MediLink Therapeutics
A clinical stage biotech company focused on developing globally competitive conjugated drugs.
Founded in 2020, MediLink has since built a differentiated proprietary tumor microenviroment activable LINker-payload (TMALIN) ADC technology platform.
It can generate homogeneous ADC, and further improve the therapeutic window in treatment of solid tumors. We focus clinical drug development on unmet medical needs and will continuously expand into new disease areas to serve the global patients.
Latest MediLink Therapeutics News & Features
3 January 2024
13 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze